Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis

MLA

Yerye Gibrán Mayén-Lobo, et al. “Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis.” Pharmaceuticals, vol. 14, no. 2, Feb. 2021, p. 118. EBSCOhost, https://doi.org/10.3390/ph14020118.

APA

Yerye Gibrán Mayén-Lobo, José Jaime Martínez-Magaña, Blanca Estela Pérez-Aldana, Alberto Ortega-Vázquez, Alma Delia Genis-Mendoza, David José Dávila-Ortiz de Montellano, Ernesto Soto-Reyes, Humberto Nicolini, Marisol López-López, & Nancy Monroy-Jaramillo. (2021). Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis. Pharmaceuticals, 14(2), 118. https://doi.org/10.3390/ph14020118

Chicago

Yerye Gibrán Mayén-Lobo, José Jaime Martínez-Magaña, Blanca Estela Pérez-Aldana, Alberto Ortega-Vázquez, Alma Delia Genis-Mendoza, David José Dávila-Ortiz de Montellano, Ernesto Soto-Reyes, Humberto Nicolini, Marisol López-López, and Nancy Monroy-Jaramillo. 2021. “Integrative Genomic–Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis.” Pharmaceuticals 14 (2): 118. doi:10.3390/ph14020118.